Beam Therapeutics (MEX:BEAM) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BEAM Beam Therapeutics Inc MEX:BEAM
70 GF Score
Price MXN535.00
GF Value MXN545.88
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Beam Therapeutics Net Loan?

Net Loan only applies to banks and insurance companies.

MEX:BEAM
70GF Score
Beam Therapeutics Inc MEX:BEAM
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be undervalued. The current stock price of MXN535.00 is trading 2% below its estimated GF Value™ of MXN545.88. GuruFocus considers Beam Therapeutics to be Modestly Undervalued.

Key valuation signals for MEX:BEAM:

  • Net Loan:
  • GF Value™: MXN545.88 vs. price of MXN535.00 (2% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
70GF Score

Get the complete analysis for MEX:BEAM

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN535.00
Price
MXN545.88
GF Value